Aligos Therapeutics to Announce 2nd Quarter 2025 Financial Results on August 6, 2025
Aligos Therapeutics (Nasdaq: ALGS), a clinical stage biotech company specializing in liver and viral disease therapies, has scheduled its Q2 2025 financial results announcement for Wednesday, August 6, 2025. The results will be released after U.S. financial markets close.
Aligos Therapeutics (Nasdaq: ALGS), una società biotecnologica in fase clinica specializzata in terapie per malattie del fegato e virali, ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per mercoledì 6 agosto 2025. I risultati saranno divulgati dopo la chiusura dei mercati finanziari statunitensi.
Aligos Therapeutics (Nasdaq: ALGS), una empresa biotecnológica en etapa clínica especializada en terapias para enfermedades hepáticas y virales, ha programado el anuncio de resultados financieros del segundo trimestre de 2025 para el miércoles 6 de agosto de 2025. Los resultados se publicarán después del cierre de los mercados financieros en EE. UU.
Aligos Therapeutics (Nasdaq: ALGS)는 간 및 바이러스 질환 치료제를 전문으로 하는 임상 단계 바이오텍 회사로, 2025년 2분기 재무 실적 발표를 2025년 8월 6일 수요일에 예정하고 있습니다. 실적은 미국 금융 시장 마감 후에 공개될 예정입니다.
Aligos Therapeutics (Nasdaq : ALGS), une société biotechnologique en phase clinique spécialisée dans les thérapies des maladies hépatiques et virales, a programmé l'annonce des résultats financiers du deuxième trimestre 2025 pour le mercredi 6 août 2025. Les résultats seront publiés après la clôture des marchés financiers américains.
Aligos Therapeutics (Nasdaq: ALGS), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf Therapien für Leber- und Viruskrankheiten spezialisiert hat, hat die Veröffentlichung der Finanzergebnisse für das zweite Quartal 2025 für Mittwoch, den 6. August 2025 geplant. Die Ergebnisse werden nach Börsenschluss in den USA veröffentlicht.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company’s second quarter 2025 financial results on Wednesday, August 6, 2025, after the close of the U.S. financial markets.
About Aligos
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics with high unmet medical needs such as chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses.
For more information, please visit www.aligos.com or follow us on LinkedIn or X.
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Such forward-looking statements are subject to substantial risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical stage of development, the process of designing and conducting clinical trials and the regulatory approval processes. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 6, 2025 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.
Company
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
(650) 910-0427
jtarazi@Aligos.com
FAQ
When will Aligos Therapeutics (ALGS) release Q2 2025 earnings?
What is Aligos Therapeutics (ALGS) main business focus?
Where can investors access ALGS Q2 2025 financial results?
What stock exchange is Aligos Therapeutics listed on?
